Contents
Inflammatory bowel disease, or IBD, is a group of chronic inflammatory conditions that includes Crohn’s disease and ulcerative colitis. Although diarrhea, abdominal pain, rectal bleeding, and bowel urgency are well-known warning signs, intestinal inflammation can also affect health throughout the body.
For some people, the first clues are less obviously digestive: persistent fatigue, iron-deficiency anemia, declining exercise tolerance, joint pain, mouth sores, eye discomfort, skin changes, unexplained weight loss, or recurring vitamin and mineral deficiencies. Extraintestinal manifestations can affect the joints, skin, eyes, bones, kidneys, liver, and other systems.
Inflammatory bowel disease testing is not one diagnostic blood test. It is a connected process that looks for objective inflammation, excludes infections that may resemble IBD, identifies anemia or nutrient loss, supports gastroenterology evaluation, and helps monitor established disease.
Ulta Lab Tests provides direct online access to many relevant blood and stool tests where direct-access testing is available. These results may help patients prepare for more informed conversations with healthcare professionals. Laboratory testing does not replace a medical examination, endoscopy, imaging, biopsy, or professional medical advice.
Direct answer: Blood and stool tests can reveal evidence of intestinal or systemic inflammation and identify complications such as anemia, iron depletion, nutrient deficiencies, dehydration, and low protein status. Crohn’s disease and ulcerative colitis are generally confirmed through gastroenterology evaluation, endoscopy with biopsies, and imaging when appropriate.
Direct answer: Inflammatory bowel disease is chronic, immune-mediated inflammation of the digestive tract. Its two principal forms, Crohn’s disease and ulcerative colitis, differ in where and how deeply inflammation affects the intestine.
Crohn’s disease may involve any part of the digestive tract from the mouth to the anus, although it frequently affects the end of the small intestine and the beginning of the colon. Inflammation can occur in separated or “skip” areas and may extend deeper through the intestinal wall.
Ulcerative colitis affects the colon and rectum. Its inflammation generally begins in the rectum and extends continuously through part or all of the colon, primarily involving the intestinal lining.
| Feature | Crohn’s disease | Ulcerative colitis |
|---|---|---|
| Typical location | May affect any part of the digestive tract; the ileum and colon are common sites | Limited to the colon and rectum |
| Pattern | Frequently patchy, with areas of healthy tissue between inflamed sections | Generally continuous, beginning in the rectum |
| Depth | May extend through deeper layers of the bowel wall | Primarily affects the inner lining |
| Common digestive clues | Diarrhea, abdominal pain, weight loss, nausea, reduced appetite, and sometimes rectal bleeding | Bloody diarrhea, rectal bleeding, urgency, mucus, abdominal cramping, and tenesmus |
| Potential complications | Strictures, fistulas, abscesses, malabsorption, and perianal disease | Severe colitis, heavy bleeding, and toxic megacolon |
| Confirmation | Endoscopy and biopsies; small-bowel imaging or other studies may be needed | Colonoscopy or flexible sigmoidoscopy with biopsies |
Symptoms overlap with many other conditions. Infection, celiac disease, irritable bowel syndrome, medication effects, diverticular disease, microscopic colitis, and other digestive disorders can produce diarrhea, abdominal discomfort, or altered bowel habits. That is why symptoms alone cannot reliably determine whether a person has IBD.
Intestinal inflammation can create whole-body effects through several pathways:
These effects help explain why someone with IBD may report exhaustion, shortness of breath during exercise, weakness, dizziness, poor concentration, muscle loss, bone concerns, or joint pain—even when diarrhea is not the most prominent symptom.
| Symptom or risk factor | What it may suggest | Related tests that may provide information |
|---|---|---|
| Persistent diarrhea or nocturnal diarrhea | Intestinal inflammation, infection, celiac disease, medication effects, or another digestive disorder | Fecal calprotectin, fecal lactoferrin, CBC, CMP, CRP, ESR, and gastrointestinal pathogen testing when appropriate |
| Rectal bleeding, blood, or mucus | Colonic or rectal inflammation, infection, hemorrhoids, polyps, or another bleeding source | CBC, ferritin and iron studies, and fecal inflammatory markers; prompt clinical evaluation may be needed |
| Bowel urgency or tenesmus | Rectal or colonic inflammation | Fecal calprotectin, fecal lactoferrin, and CRP; endoscopic evaluation may be needed |
| Unexplained weight loss | Active inflammation, inadequate intake, malabsorption, endocrine disease, or another illness | CBC, CMP, CRP, ESR, iron studies, vitamin B12 and folate, vitamin D, and TSH with Free T4 when indicated |
| Fatigue or poor exercise tolerance | Anemia, iron depletion, inflammation, dehydration, electrolyte loss, or nutrient deficiency | CBC, ferritin, iron, and TIBC, vitamin B12 and folate, CMP, magnesium, and CRP |
| Joint pain or swelling | An extraintestinal inflammatory manifestation or an unrelated joint disorder | CRP, ESR, and CBC; additional testing should be directed by symptoms and clinical examination |
| Eye redness, light sensitivity, or eye pain | Possible inflammatory eye involvement | Prompt eye and medical evaluation; blood testing alone is insufficient |
| Mouth sores or skin changes | Possible extraintestinal inflammation or nutrient deficiency | CBC, ferritin and iron studies, vitamin B12 and folate, zinc, and CRP; clinical evaluation is also important |
| Recurrent anemia or low ferritin | Chronic blood loss, inadequate intake, inflammation, or malabsorption | CBC, ferritin, iron, and TIBC panel, CRP, and vitamin B12 and folate panel |
| Family history of IBD | Increased susceptibility, especially when symptoms are present | Symptom-directed intestinal inflammatory testing and nutritional testing; gastroenterology evaluation when warranted |
| Ileal Crohn’s disease or ileal surgery | Increased risk of vitamin B12 or bile acid absorption problems | Vitamin B12 test, methylmalonic acid test when appropriate, CBC, folate test, and vitamin D test |
| Repeated corticosteroid exposure | Bone loss, glucose changes, and other medication effects | Vitamin D, calcium, phosphorus, glucose, or A1c; bone-density evaluation is not a blood test |
Safety note: Heavy rectal bleeding, black or tarry stools, severe or rapidly worsening abdominal pain or swelling, persistent vomiting, fainting, confusion, high fever, marked weakness, or signs of severe dehydration require urgent medical care rather than routine direct-access testing.
Direct answer: Laboratory tests can identify inflammation and complications, but they usually cannot determine by themselves whether the cause is Crohn’s disease, ulcerative colitis, infection, or another disorder.
Laboratory testing helps answer four practical questions:
Blood testing can identify anemia, systemic inflammation, electrolyte abnormalities, low albumin, liver or kidney changes, and nutritional deficiencies. Stool testing can provide more direct evidence of intestinal inflammation and help identify selected infections.
What laboratory tests cannot do is show the location, depth, or microscopic pattern of the inflammation. Endoscopy is central to diagnosing Crohn’s disease, while ulcerative colitis is confirmed through large-intestinal endoscopy with biopsies. Imaging may also be needed for suspected small-bowel Crohn’s disease, narrowing, fistulas, or abscesses.
The following tests should be selected according to symptoms, medical history, prior results, and clinician recommendations. Not every patient needs every test.
| Test or biomarker | What it measures | Why it may be relevant | General result pattern | Important limitations |
|---|---|---|---|---|
| Calprotectin Stool Test | Calprotectin released by inflammatory cells in the intestine | Helps identify an inflammatory intestinal pattern and monitor established IBD | Higher results may indicate intestinal inflammation | Infection, medication-related injury, and other intestinal conditions can elevate it; it does not distinguish Crohn’s disease from ulcerative colitis |
| Lactoferrin Quantitative Stool Test | A protein released by activated white blood cells in stool | Provides another marker of intestinal inflammation | Elevated results support active intestinal inflammation | Nonspecific; it cannot identify the cause or location |
| C-Reactive Protein Test | A liver-produced acute-phase protein | Measures systemic inflammatory activity | Elevation may accompany active inflammation or infection | Some patients with active IBD have little or no CRP elevation |
| Sed Rate Test (ESR) | The rate at which red blood cells settle | Provides a broad, slower-changing marker of inflammation | Higher results may occur with inflammation, anemia, infection, age, or other conditions | Less specific and slower to respond than CRP |
| Complete Blood Count with Differential and Platelets | Red cells, hemoglobin, white cells, and platelets | Detects anemia and blood-cell patterns associated with bleeding, inflammation, infection, or medication effects | Low hemoglobin suggests anemia; elevated white cells or platelets may accompany inflammation | A normal CBC does not rule out early iron depletion or intestinal inflammation |
| Comprehensive Metabolic Panel (CMP) | Electrolytes, kidney markers, liver enzymes, albumin, total protein, glucose, and calcium | Assesses dehydration, electrolyte loss, organ function, and protein status | Low albumin or electrolyte abnormalities may reflect disease burden or losses | Albumin is affected by inflammation, liver function, kidney loss, and hydration—not nutrition alone |
| Ferritin, Iron and TIBC Panel | Stored iron, circulating iron, iron-binding capacity, and transferrin saturation | Evaluates iron depletion and mixed iron-deficiency/inflammatory anemia patterns | Low ferritin or transferrin saturation can support iron deficiency | Ferritin can rise during inflammation, potentially obscuring deficiency |
| Vitamin B12 and Folate Panel Test | Vitamins needed for red-cell and neurologic function | Relevant with anemia, restricted intake, ileal disease, ileal surgery, or neurologic symptoms | Low values may indicate deficiency | Serum B12 may be borderline or misleading; a Methylmalonic Acid Test may provide clarification |
| Vitamin D 25-Hydroxy Total Test | The primary circulating vitamin D marker | Relevant to bone health, malabsorption, low body weight, and corticosteroid exposure | A low result indicates reduced vitamin D status | Varies with supplementation, season, sun exposure, and assay |
| Magnesium Test and Zinc Test | Circulating mineral concentrations | May be considered with chronic diarrhea, restricted intake, poor wound healing, or suspected losses | Low results may indicate deficiency or ongoing loss | Serum levels do not always represent total body stores |
| Clostridioides difficile Toxin B Qualitative Test | Bacterial genetic material associated with toxin B | Helps evaluate an infection that may mimic or worsen IBD | A positive result requires clinical interpretation | Testing asymptomatic people or formed stool can be misleading; follow specimen instructions |
| Gastrointestinal Pathogen Panel | Selected bacterial, viral, or parasitic gastrointestinal pathogens, depending on the assay | May help evaluate new, severe, travel-related, or suddenly worsening diarrhea | A detected pathogen may explain or complicate symptoms | Panel composition and clinical relevance vary; results require medical context |
| Hepatitis B Titer Test Panel and QuantiFERON-TB Gold Plus Tuberculosis Test | Evidence of hepatitis B infection or immunity and immune response to tuberculosis antigens | Commonly considered before selected biologic or advanced immune-modifying therapies | Positive, negative, or indeterminate findings require clinician-directed interpretation | Exact screening requirements depend on the planned treatment and individual risk history |
| Pregnancy Blood Test | Qualitative human chorionic gonadotropin, or hCG | May be needed before selected therapies or procedures when pregnancy is possible | A positive result indicates detected hCG | Timing and clinical context affect interpretation |
| Medication-specific CBC, Hepatic Panel, Creatinine Test, and Lipid Panel Test | Potential treatment effects on blood cells, liver, kidneys, and lipids | Used to establish a baseline and monitor selected therapies | Abnormalities may require clinician review or repeat testing | Monitoring schedules depend on the medication |
| Biologic drug levels and anti-drug antibodies | Medication concentration and immune antibodies to a biologic | May help evaluate loss of treatment response in selected patients | Low drug levels or detected antibodies may inform specialist decisions | Not a general screening test; timing and interpretation are medication-specific |
Fecal calprotectin and fecal lactoferrin are intestinal inflammatory markers; CRP and ESR are systemic and nonspecific. A CBC, albumin-containing CMP, and nutrient markers provide information about disease burden and complications rather than confirming an IBD subtype.
For persistent diarrhea, rectal bleeding, nocturnal symptoms, bowel urgency, unexplained weight loss, anemia, fever, or a family history of IBD, an initial laboratory discussion may include:
This combination looks for intestinal inflammation, systemic inflammation, anemia, protein changes, dehydration, and iron depletion.
Additional testing may be appropriate when specific clues are present:
These tests evaluate complications and overlapping conditions. They do not independently confirm IBD.
An elevated fecal calprotectin or CRP supports further investigation but does not identify the specific cause. Gastroenterology evaluation may include:
Endoscopic and imaging findings help determine the location, severity, and type of inflammation.
Before selected biologic or advanced small-molecule treatments, clinician-directed testing may include:
Medication-specific screening and monitoring should follow the prescribing clinician’s plan.
For established Crohn’s disease or ulcerative colitis, monitoring may include repeat:
The schedule should be set by the prescribing or treating clinician.
Reference ranges vary by laboratory, assay, age, sex, pregnancy status, and specimen type. A value marked outside the range is not automatically proof of IBD, and a value within range does not always rule it out.
Fecal calprotectin thresholds are context-dependent. Clinical guidance has described a range around 50–100 µg/g as useful for distinguishing inflammatory from noninflammatory colonic disease in selected diagnostic settings. That is a triage concept, not a universal diagnostic line.
For people with established ulcerative colitis who are in symptomatic remission, biomarker guidance may use fecal calprotectin below 150 µg/g, normal fecal lactoferrin, or normal CRP as evidence that active inflammation is less likely. For Crohn’s disease, fecal calprotectin below 150 µg/g and CRP below 5 mg/L may help rule out active inflammation in certain clinically defined situations.
These thresholds are not interchangeable. Assay differences, disease location, symptoms, previous endoscopy, and treatment status all matter.
CRP measures inflammation throughout the body. Some people do not produce a strong CRP response even when intestinal inflammation is present. Fecal calprotectin, fecal lactoferrin, symptoms, endoscopy, imaging, and previous response patterns may provide necessary context.
Ferritin reflects stored iron, but it also behaves as an acute-phase reactant and may rise during inflammation. A normal or elevated ferritin therefore does not always guarantee adequate usable iron.
The Ferritin, Iron and TIBC Panel should be interpreted alongside hemoglobin from a CBC and an inflammatory marker such as CRP.
A connected pattern is more informative than one isolated value. Examples include:
When symptoms and biomarkers disagree, additional assessment—often repeat biomarkers, endoscopy, or imaging—may be more appropriate than automatically changing medication.
Where direct-access testing is available, patients can order many relevant blood and stool tests online through Ulta Lab Tests. Patients can review transparent pricing before ordering, no insurance is required, HSA or FSA payment may be available for eligible purchases, and results are delivered securely online.
Direct access may help patients:
Specimen collection is performed through established laboratory networks such as Quest Diagnostics where applicable. Ulta Lab Tests does not replace a gastroenterologist, diagnose Crohn’s disease or ulcerative colitis, select medication, or supervise treatment. Learn more about the ordering process on the How It Works page.
Explore Inflammatory Bowel Disease Lab Tests
Common blood tests include a Complete Blood Count with Differential and Platelets, C-Reactive Protein Test, Sed Rate Test, Comprehensive Metabolic Panel, Ferritin, Iron and TIBC Panel, Vitamin B12 and Folate Panel Test, and Vitamin D 25-Hydroxy Total Test. These tests can identify systemic inflammation, anemia, protein changes, dehydration, or nutrient deficiencies. They may support an IBD evaluation, but they cannot confirm Crohn’s disease or ulcerative colitis without appropriate medical evaluation.
The Calprotectin Stool Test is commonly used to help distinguish an inflammatory intestinal pattern from a noninflammatory condition such as irritable bowel syndrome. The Lactoferrin Quantitative Stool Test provides related information. An elevated result does not prove IBD because infections, medications, and other inflammatory disorders may also increase these markers.
No. A normal C-Reactive Protein Test result makes a strong systemic inflammatory response less likely, but some people with active intestinal inflammation have a normal or only slightly elevated CRP. Fecal calprotectin, fecal lactoferrin, endoscopy, biopsies, imaging, and the person’s previous biomarker response may provide additional information.
Yes. Fatigue may be related to systemic inflammation, iron deficiency, anemia, vitamin B12 or folate deficiency, low vitamin D, dehydration, inadequate calorie intake, poor sleep, medication effects, or another condition. A connected evaluation may include a CBC, Ferritin, Iron and TIBC Panel, CRP, CMP, Vitamin B12 and Folate Panel, Vitamin D Test, and thyroid testing when symptoms warrant.
Ferritin reflects stored iron but also rises in response to inflammation. During active IBD, a ferritin result that appears normal—or even elevated—may coexist with inadequate available iron. Reviewing the Ferritin, Iron and TIBC Panel together with hemoglobin from a CBC and an inflammatory marker such as CRP provides a more complete picture.
No. An elevated Calprotectin Stool Test result indicates that intestinal inflammation may be present, but it does not identify the cause. Crohn’s disease, ulcerative colitis, gastrointestinal infection, diverticulitis, some medication-related injuries, and other inflammatory conditions can elevate the result. Diagnosis usually requires gastroenterology evaluation, endoscopy with biopsies, and imaging when appropriate.
Ulta Lab Tests provides direct online access to many inflammation, anemia, nutritional, metabolic, and stool tests where direct-access testing is available. Direct ordering can help patients obtain objective information and prepare for a healthcare appointment. It does not replace a clinician, and endoscopy, imaging, prescription monitoring, or urgent evaluation must still be arranged through qualified healthcare professionals.
The appropriate interval depends on whether the Calprotectin Stool Test or C-Reactive Protein Test is being used for initial evaluation, after a treatment change, during symptomatic remission, or for a suspected flare. Established IBD should be monitored according to a gastroenterologist’s plan. Repeating a test may be helpful when a result is borderline or conflicts with symptoms.
Clinician-directed baseline testing commonly includes a CBC, CMP or Hepatic Panel, Hepatitis B Titer Test Panel, QuantiFERON-TB Gold Plus Tuberculosis Test, and a Pregnancy Blood Test when applicable. Some medications also require a Lipid Panel Test or other monitoring. Exact requirements vary by drug, health history, and infection risk.
Seek urgent medical attention for heavy rectal bleeding, black or tarry stools, fainting, confusion, severe dehydration, persistent vomiting, high fever, rapidly worsening abdominal swelling, or severe abdominal pain. These symptoms may indicate significant bleeding, obstruction, severe inflammation, infection, or another complication that should not be evaluated through routine direct-access testing alone.
Inflammatory bowel disease can affect much more than bowel habits. Crohn’s disease and ulcerative colitis may contribute to anemia, iron depletion, fatigue, nutrient deficiencies, joint symptoms, bone concerns, and poor exercise tolerance—even when digestive symptoms do not tell the full story.
A thoughtful inflammatory bowel disease testing pathway combines stool markers of intestinal inflammation with blood tests for systemic inflammation, anemia, nutritional status, organ function, and treatment safety. No single laboratory result confirms or excludes IBD, but connected testing can reveal patterns that support timely, informed conversations with a healthcare professional.
Explore relevant inflammatory bowel disease lab tests through Ulta Lab Tests, and review your results with a qualified healthcare provider who can determine whether endoscopy, imaging, repeat testing, or specialist care is appropriate.
View IBD Blood and Stool Tests
Definition: Inflammatory bowel disease testing uses blood and stool tests to look for objective inflammation and complications associated with Crohn’s disease and ulcerative colitis. Laboratory results can support evaluation and monitoring, but diagnosis generally requires medical assessment, endoscopy with biopsies, and imaging when appropriate.
Related tests: Calprotectin Stool Test, Lactoferrin Quantitative Stool Test, Complete Blood Count with Differential and Platelets, C-Reactive Protein Test, Sed Rate Test, Comprehensive Metabolic Panel, Ferritin, Iron and TIBC Panel, Vitamin B12 and Folate Panel Test, Vitamin D 25-Hydroxy Total Test, Magnesium Test, Zinc Test, Clostridioides difficile Toxin B Qualitative Test, Hepatitis B Titer Test Panel, and QuantiFERON-TB Gold Plus Tuberculosis Test.
How Ulta Lab Tests helps: Ulta Lab Tests helps patients access many relevant blood and stool tests directly online where available, with transparent pricing and secure online results.
Disclaimer: Laboratory testing is informational and should be interpreted by a qualified healthcare professional alongside symptoms, medical history, medications, endoscopy, imaging, and other findings.
The iron panel is the most appropriate article link for serum iron, TIBC, and calculated transferrin saturation.
The celiac panel belongs in the overlap and differential-evaluation section rather than being presented as an IBD diagnostic test.
These tests are relevant to fatigue, weight change, and altered bowel habits but should not be characterized as IBD-specific markers.
The article may also cross-reference the previously linked CBC, hepatic panel, creatinine, and lipid panel as medication-specific baseline or follow-up safety tests. Hepatitis B and tuberculosis screening pages are currently represented on the Ulta site through the linked titer and QuantiFERON products.
Medication-specific biologic drug-level and anti-drug-antibody testing varies according to the prescribed therapy. Rather than directing every reader to one assay, link the general phrase to the main:
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
